$1.15 billion of financing within 15days: From Fitness Tracking to Health Tracking: Is Longevity Becoming the Next Consumer Category?

Executive Summary

The most important shift is not simply that longevity is becoming fashionable. It is that consumers are gaining direct access to increasingly sophisticated health information.

Neko Health raised $700 million in July 2026. Function Health secured $450 million later the same month. Prenuvo, Superpower, Axo Longevity and other businesses are building around similar themes: bloods, imaging, wearables, AI interpretation and repeated monitoring.

For investors, the proposition is attractive because these businesses can create recurring relationships, longitudinal data, membership revenue and cross-category expansion.

For aesthetic clinics, the implication is more complex.

Customers may increasingly arrive already tracking sleep, glucose, body composition, blood biomarkers, cardiovascular risk and biological-age indicators. That changes expectations around personalisation and may blur the boundary between aesthetics, wellness and preventative health.

The strongest opportunity may not be for every aesthetics clinic to become a longevity clinic. It may be for clinics to decide where they sit within a broader health ecosystem.

What does this mean for aesthetic clinics?

The core issue is customer behaviour.

Historically, many patients entered an aesthetic clinic with a visible concern: skin quality, ageing, facial structure, hair loss or body contouring.

Increasingly, that same customer may also be tracking metabolic health, sleep, nutrition, body composition and biomarkers independently.

The objectives start to overlap:

Appearance | Skin quality | Weight | Body composition | Strength | Energy | Metabolic health | Healthy ageing

That creates an opportunity for some clinics to broaden their role, but also a risk of moving into healthcare services without the clinical capability or governance to support them.

The strategic choice is likely to fall into three models: remain a specialist aesthetics provider; partner with diagnostic, nutrition and health services; or build a genuinely integrated health and longevity proposition.

The important distinction is that the third option is not simply “adding longevity”. It means building a healthcare capability.

The conclusion

The Harley view is that the consumer may move into longevity faster than the aesthetics industry does.

Wearables, private blood testing, imaging and AI health platforms are already making personalised health information increasingly accessible outside traditional healthcare pathways.

That means the future opportunity for aesthetics may not be about owning every part of the health journey.

It may be about becoming a trusted part of it.

Clinics that understand where aesthetics ends, where preventative health begins and where partnerships make more sense than ownership may be better positioned than those simply adding longevity terminology to an existing treatment menu.

The capital flowing into Neko, Function and adjacent platforms suggests investors increasingly see preventative health as a scalable consumer category.

The question is whether aesthetics becomes part of that category — or remains adjacent to it.

Why investors are paying attention

The scale of recent investment is significant.

Neko Health raised $700 million in Series C funding on 15 July 2026. The business combines a one-hour health assessment with proprietary scanning technology, blood analysis, body composition and clinician review.

By the time of the raise, Neko said more than 100,000 people had completed its health scan across the UK and Sweden, with more than 350,000 registered or waiting. The company also reported that around 75% of members booked and prepaid for a repeat scan. [1]

That repeat behaviour matters.

The proposition is not simply a one-off diagnostic event. It creates the potential for a recurring consumer relationship built around measurement and reassessment.

Function Health approaches the same opportunity from a different angle.

On 30 July 2026, Function announced $450 million in growth financing from General Catalyst’s Customer Value Fund. Its model centres on laboratory testing, imaging and personalised health intelligence, designed to build a longitudinal picture of the consumer rather than an isolated set of results. [2]

Function has also expanded into the surrounding infrastructure. It acquired Getlabs’ blood-draw network and SuppCo, a supplement-management platform.

That starts to reveal the broader commercial thesis.

The value may not sit in the blood test alone.

It may sit in the platform that connects testing, data, interpretation, recommendations, supplements and repeat monitoring.

A broader category is emerging

Neko and Function are not isolated examples.

Prenuvo raised $120 million in Series B funding in 2025 to expand its preventative whole-body MRI proposition and associated AI capabilities. Its model has expanded beyond imaging alone, incorporating broader health information and biomarker analysis. [3]

Superpower raised $30 million in Series A funding, building around extensive blood testing, physician access and personalised health management. [4]

Axo Longevity raised $5 million in September 2026 to expand a European preventative-health membership incorporating biomarkers, AI and wearable integrations. [5]

The businesses are different in size and structure, but the underlying direction is similar.

Consumers are moving from passive health information towards continuous measurement and optimisation.

From fitness data to health data

The progression is relatively easy to see.

Consumer fitness technology initially focused on activity: steps, heart rate, workouts and calories.

It then expanded into recovery: sleep, heart-rate variability and stress.

Now the category is moving deeper into health: blood biomarkers, glucose, imaging, body composition, cardiovascular risk and potentially broader biological-age measures.

The journey is moving from:

Activity → Recovery → Biomarkers → Imaging → Interpretation → Intervention

That is where fitness, nutrition, wellness and medicine begin to overlap.

And that overlap is effectively where longevity is being built as a consumer category.

Why this matters for aesthetics

Aesthetics has historically been organised around procedures and products.

But consumers do not necessarily think in those categories.

Someone experiencing significant weight loss may simultaneously be thinking about body composition, muscle preservation, facial volume, skin laxity, hair health and nutrition.

Someone interested in healthy ageing may see skincare, sleep, exercise, metabolic health and aesthetics as part of the same objective.

That does not mean one provider should manage every element.

It does mean the customer journey is becoming more connected.

For aesthetic clinics, the commercial opportunity may therefore move from selling isolated treatments towards participating in a broader, longer-term relationship around appearance and ageing.

Should clinics offer blood testing?

Not necessarily.

This is where the market could easily move too far, too quickly.

Access to more biomarkers does not automatically produce better care.

Testing large numbers of markers in healthy people can generate abnormal findings, uncertainty and further investigation. Interpretation matters. Clinical responsibility matters. Referral pathways matter.

The strongest models in this emerging market recognise that.

Neko includes clinician review. Prenuvo uses medical professionals and radiologists. Other platforms increasingly combine technology with physician access.

That suggests the defensible proposition may not be testing alone, but rather:

Measurement → Interpretation → Action → Follow-up

For an aesthetics clinic, that raises a simple question.

Does the clinic genuinely have the clinical infrastructure to manage that pathway?

If not, partnership may be more credible than ownership.

The clinic advantage

Aesthetic clinics do, however, have one important advantage.

They already operate physical locations.

They already have regular consumer contact.

They already work in a private-pay environment.

And many already maintain long-term relationships with customers.

That infrastructure is valuable.

The opportunity may therefore be for selected clinics to connect into diagnostic, nutrition, fitness and medical services without needing to recreate every capability internally.

In that model, the clinic becomes one component in a wider ecosystem.

The Harley View

The direction of travel is becoming clearer.

Health is becoming more measurable.

Consumers are becoming more informed.

Technology is reducing the distance between consumer wellness and traditional diagnostics.

And capital is increasingly backing businesses capable of turning health data into a recurring service.

For aesthetics, the implication is not that every clinic should become a longevity clinic.

It is that the definition of the customer relationship is expanding.

The clinics that benefit may be those that understand that shift early — and decide deliberately whether they want to remain specialists, build partnerships or evolve into broader health businesses.

References

[1] Neko Health — Neko Health raises $700m Series C ahead of US launch — 15 July 2026
https://www.nekohealth.com/gb/en/press/neko-health-raises-usd700m-series-c-ahead-of-us-launch

[2] Function Health — Function secures $450 million growth financing — 30 July 2026
https://www.prnewswire.com/news-releases/function-secures-450-million-growth-financing-from-general-catalysts-customer-value-fund-cvf-302838766.html

[3] Prenuvo — $120m Series B
https://prenuvo.com/uk/announcements/prenuvo-announces-it-had-raised-120m-to-advance-preventative-health-launches-novel-fda-cleared-ai-powered-products

[4] Superpower — $30m Series A
https://superpower.com/series-a

[5] Axo Longevity — $5m seed round
https://www.axolongevity.com/en-gb/resources/axo-longevity-raised-an-oversubscribed-5m-seed-round-to-make-preventive-healthcare-accessible-across-europe

This version is much closer to the Harley style you’ve been moving toward: conclusion early, investor relevance clear, then evidence underneath.